

**Correction to
Lancet Neurol 2024;
23: 500–10**

Wisch JK, McKay NS, Boerwinkle AH, et al. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study. *Lancet Neurol* 2024; **23**: 500–10—In this Article, the colours in the key for parts D, E, and F of figure 3 have been swapped, and the labels for the vertical lines in figure 3D have been swapped. These corrections have been made to the online version as of April 16, 2025.

**Correction to
Lancet Neurol 2025;
24: 290**

Drouin E, Tatu L, Hautecoeur P. Augusta Dejerine-Klumpke, a neurologist ahead of her time. *Lancet Neurol* 2025; **24**: 290—In this Focal Point, the spelling of author Patrick Hautecoeur's name was incorrect. This correction has been made to the online version as of April 16, 2025.

**Correction to
Lancet Neurol 2024;
23: 1013–24**

Allen JA, Lin J, Basta I, et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol* 2024; **23**: 1013–24—In this Article, corrections have been made to definitions of safety populations in tables 1 and 3, the first footnote of table 1, and the indentation of "Atypical CIDP" row of table 1, and the appendix has also been corrected. These corrections have been made to the online version as of March 25, 2025.



Published Online
March 25, 2025
[https://doi.org/10.1016/S1474-4422\(25\)00108-5](https://doi.org/10.1016/S1474-4422(25)00108-5)